Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
Recruiting · NCT04231565 · Interventional (participants receive a specific treatment) · Lead sponsor: Third Affiliated Hospital, Sun Yat-Sen University
View the official record on ClinicalTrials.gov →Interventions studied
Tenofovir alafenamide Fumarate
What this trial is about
This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Positive hepatitis b surface antigen and hepatitis b antibody \> 0.5 year;
- Age from 18 to 65 years old;
- Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;
- Positive Hepatitis b virus(HBV);
- Do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year.
Exclusion criteria
- Other active liver diseases;
- Hepatocellular carcinoma or other malignancy;
- Pregnancy or lactation;
- Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.
Where it is running
1 location listed.
- Third Affiliated Hospital of Sun Yat-sen University - Guangzhou, Guangdong, China